AGS1/RASD1 is a Ras-related protein identified as a dexamethasone-inducible cDNA and as a signal regulator in various functional and protein-interaction screens. As an initial approach to define the role of AGS1/RASD1 as a Ras-family member, we determined its influence on cell growth/survival. In clonogenic assays with NIH-3T3 murine fibroblast cells, the MCF-7 human breast cancer cell line and the human lung adenocarcinoma cell line A549, AGS1/RASD1 markedly diminished the number of G418-resistant colonies, whereas the Ras subgroup member K-Ras was without effect. A549 cell infection with adenovirus engineered to express AGS1/RASD1 (Ad.AGS1) inhibited log phase growth in vitro and increased the percentage of cells undergoing apoptosis. The anti-growth action was also observed in vivo as the expression of AGS1/RASD1 inhibited the subcutaneous tumor growth of A549 cells in athymic nude mice. These data indicate that AGS1/RASD1, a member of the Ras superfamily of small G-proteins that often promotes cell growth and tumor expansion, plays an active role in preventing aberrant cell growth.
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Keywords: AGS1; RASD1; Dexras1; G-protein; apoptosis; cancer AGS1/RASD1 is a member of the Ras superfamily of small G-proteins and is most similar to the Ras subgroup involved in cell growth, differentiation and transformation (Kemppainen and Behrend, 1998; Cismowski et al., 1999; Takai et al., 2001) . AGS1/RASD1 and a related Ras-family member Rhes/TEM2 (RASD2), which exhibits 60% amino-acid sequence identity with AGS1/RASD1, apparently define a distinct subgroup within the larger Ras group of proteins. AGS1/RASD1 was first discovered as a dexamethasone-inducible cDNA (Dexras1) in AtT-20 mouse corticotroph cells (Kemppainen and Behrend, 1998) and subsequently as a receptor-independent activator of heterotrimeric G-protein signaling (hence its name Activator of G-protein Signaling) in a yeastbased functional screen of mammalian cDNAs Takesono et al., 1999) . As both AGS1/RASD1 and Rhes/TEM2/RASD2 can influence signaling pathways involving heterotrimeric G-proteins (Cismowski et al., , 2000 Graham et al., 2001 Graham et al., , 2002 Takesono et al., 2002; Vargiu et al., 2004) , they provide interesting points for signal integration and cross-talk. AGS1/RASD1 is also involved in other signaling pathways as it forms an apparent ternary complex with neuronal nitric oxide synthase (nNOS) and the nNOS binding protein CAPON, where the activation of AGS1/ RASD1 is suggested to involve S-nitrosylation (Fang et al., 2000; Jaffrey et al., 2002) .
As a Ras family member, AGS1/RASD1 may regulate various aspects of cell growth and differentiation, and mutations in Ras proteins that confer constitutive activity are commonly identified in many different types of tumors (Der, 1989) . Both AGS1/ RASD1 and K-Ras contain a consensus site for farnesylation at their carboxyl termini. However, the two proteins differ in key amino acids within the effector domain and the size of the carboxyl extension that separates the Ras core motif from the carboxyl terminus. As an initial approach to define the role of AGS1/RASD1 as a Ras family member, we focused on the effect of AGS1/RASD1 on cell growth/survival. In clonogenic assays with NIH-3T3 murine fibroblast cells, the MCF-7 human breast cancer cell line and the human lung adenocarcinoma cell line A549, AGS1/RASD1 transfection markedly diminished the number of G418-resistant colonies, whereas K-Ras, another member of the Ras protein family, was without effect. A549 cell infection with adenovirus engineered to express AGS1/ RASD1 (Ad.AGS1) inhibited log phase growth in vitro and increased the percentage of cells undergoing apoptosis. The anti-growth action was also observed in vivo as the expression of AGS1/RASD1 inhibited the subcutaneous tumor growth of A549 cells in athymic nude mice. These data indicate that AGS1/RASD1, a member of the Ras superfamily of small G-proteins that often promotes cell growth and tumor expansion, plays an active role in preventing aberrant cell growth.
Results and Discussion
In addition to the extended carboxyl-terminus domain of AGS1/RASD1, the core effector domain and flanking regions of AGS1/RASD1 also exhibit important differences in key residues as compared to other Ras family proteins, suggesting that these two proteins regulate distinct signaling pathways. AGS1/RASD1 exhibits constitutive activity in both yeast-based screens and mammalian cells. This activity may be associated with amino acids in the phosphate/magnesium-binding domains (PM1 and PM3) that differ from the corresponding amino acids in H-Ras and K-Ras, mutation of which results in constitutive activation of these proteins. Other Ras-related proteins containing similar amino-acid differences in this region also exhibit constitutive activity (Foster et al., 1996; Luo et al., 2003) .
AGS1/RASD1 mRNA and/or protein is generally widely expressed in normal human tissues with a major mRNA species of B2.2 kb, but AGS1/RASD1 mRNA was not detected in various human cancer cell lines (HL-60, K-562, SW-480, A549, G-361, Raji and MCF-7) (Figure 1a, between a Ras family member and AGS1/RASD1 in terms of their role in growth control, we initially performed clonogenic assays with AGS1/RASD1 and K-Ras (AF493917). The latter Ras protein does not typically alter colony formation in this assay and thus serves as an internal control. Transfection of NIH-3T3 cells, which do not express detectable levels of AGS1/RASD1 (Vaidyanathan G and Lanier SM. Unpublished observations), with AGS1/RASD1 markedly diminished the number of G418-resistant colonies, whereas K-Ras had no effect ( Figure 2 ). Similar inhibition of colony formation was observed with the human His-tagged AGS1/RASD1 ( Figure 2 ). AGS1-G31V, which contains a mutation within the PM1 domain of the Ras core and exhibited a reduced activity in both the yeast functional screen and Elk activation assays in COS-7 transfectants Cismowski et al., 2000) , did not alter the number of G418-resistant colonies, providing an additional internal control for the specificity of the observed effects of wild-type AGS1/RASD1. Expansion of colonies that did grow in the AGS1/RASD1-transfected plate followed by immunoblotting indicated that, although G418-resistant, these cells did not express detectable levels of AGS1/RASD1 (Vaidyanathan G and Lanier SM. Unpublished observations). These data indicate that AGS1/RASD1, in contrast to K-Ras, actually operates to inhibit clonal cell expansion. A similar suppression of clonogenic growth by AGS1/ RASD1 was observed with the MCF-7 human breast cancer cell line and the human lung adenocarcinoma cell line A549 (Figure 2 ), which actually expresses a constitutively active form of K-Ras. Figure 1 Expression analysis of AGS1/RASD1 in (a) human tissues and (b) cell lines. CLONTECH multiple-human normal tissue blots containing 2 mg mRNA per lane were hybridized with random-primed probe generated from the coding region of human AGS1/RASD1 coding sequence. H, heart; BR, brain; PL, placenta; LU, lung; LI, liver; SK, skeletal muscle; K, kidney; PA, pancreas; U, uterus; C, colon; SI, small intestine; BL, bladder; ST, stomach; PR, prostate; SP, spleen; LY, lymph node; T, thymus; A, appendix; PBL, peripheral blood leukocyte; BO, bone marrow; FL, fetal liver. Molecular weight standards in kilobases are indicated to the left of the blots. The 2.2 kb AGS1/RASD1 transcript is indicated by arrowheads to the right of the blots. The mRNA blot in (b) was stripped after hybridization with the AGS1/RASD1 probe and hybridized with a random-primed probe from the coding region for human b-actin (lower panel). Autoradiographs were generated by exposure of the blots for 3-7 days at -701C with intensifying screens Figure 2 Clonogenic assay with AGS1/RASD1. NIH-3T3, MCF-7 and A549 cell lines, obtained from American Type Culture Collection (Manassas, VA, USA), were transfected by calcium phosphate precipitation and subjected to G418 selection (NIH-3T3: 875 mg/ml, MCF-7: 1400 mg/ml, A549: 3000 mg/ml) for 21 days (Lanier et al., 1991) . Colonies were stained with 2% methylene blue in 50% ethanol and counted by visual inspection (inset presents data for one experiment with NIH-3T3 cells). Data are presented as the percent of control colony number (means7s.e.). Control colony numbers were 115721, 160731, 22179 for NIH-3T3, MCF-7 and A549 cells, respectively. Number of experiments in duplicate: NIH-3T3 cells -K-Ras (2), AGS1 (9), His-AGS1 (5), AGS1-G31V (3), His-AGS1-G31V (3), AGS1-C277S (2); MCF-7 (3); and A549 (2) AGS1/RASD1 suppresses cell growth G Vaidyanathan et al
These data indicate that AGS1/RASD1 is actively regulating a signaling pathway that causes growth arrest or promotes cell death. To further explore this apparent 'anti-growth' action of AGS1/RASD1 and potential anti-tumor action in vivo, we generated adenoviral constructs of AGS1/RASD1. Initial screening of virus constructs in NIH-3T3, MCF-7, A549 and HeLa cells indicated a 90% infection efficiency for each cell type as indicated by GFP expression, which is incorporated into the control virus vector. The AGS1 expression level was the highest in A549 cells, which likely reflects the reasonable levels of coxsackievirus-adenovirus receptors found on the cell surface, and this cell line was selected for further study. Endogenous AGS1/RASD1 is not expressed in A549 cells, but the protein was readily detected after Ad.AGS1 infection (Figure 3a, inset) . Cells infected with Ad.AGS1 essentially did not increase in cell number over the 5-day period in marked contrast to cells infected with empty vector control (Ad.Vector) or with Ad.AGS1-G31V (Figure 3a) . In the latter case, however, immunoblotting from multiple infection experiments consistently indicated lower levels of protein expression versus wild-type AGS1/RASD1 (Figure 3a , inset). (It is not clear why the G31V mutant is expressed at lower levels following infection of A549 cells. It is thus difficult to firmly conclude that the lack of effect in cells infected with Ad.AGS1-G31V reflects the mutation itself or lower expression of the protein. However, this mutation clearly renders the protein inactive in functional assays in yeast and COS-7 cells, and this occurs when the mutant and wild-type AGS1/RASD1 are expressed at similar levels (Cismowski et al., 2000) .) The effectiveness of Ad.AGS1 in preventing cell expansion was further addressed by evaluation of subcutaneous tumor growth of A549 cells in athymic nude mice. Ad.AGS1 completely prevented the formation of tumors in mice injected with A549 cells expressing AGS1/RASD1 (Figure 3b ), but not in mice injected with A549 cells transduced with either the empty vector control (Ad.Vector) or the UV inactivated AGS1/ RASD1 adenovirus (UV-Ad.AGS1). The mice injected with AGS1-expressing cells (Ad.AGS1) remained tumorfree even at day 60 following injection.
These data suggest that the loss of AGS1/RASD1 results in aberrant cell growth and we then asked how AGS1/RASD1 may act as an apparent brake on cell growth. The actual level of AGS1/RASD1 expressed following infection with adenoviral AGS1/RASD1 constructs was only two-fold greater than that observed for endogenous expression in the rat brain, liver and heart, indicating that the effects of AGS1/RASD1 on cell growth can possibly occur in cells expressing endogenous protein (Vaidyanathan G and Lanier SM. Unpublished observations). The inhibition of clonal expansion by AGS1/RASD1 in transfected NIH-3T3 cells required an intact consensus site for farnesylation, as it was not observed with AGS1-C277S, a mutation within the CVIS consensus site at the carboxyl terminus. The inactivity of the G31V mutant and the differences in the effector domains of AGS1/RASD1 and Ras indicate that the anti-growth effect of AGS1/RASD1 is not simply due to 'chelation' of Ras effectors. Indeed, the expression of wild-type AGS1/RASD1 in COS-7 cells did not interfere with the activation of ERK2 by epidermal growth factor or the G-protein-coupled Figure 3 Influence of adenoviral-mediated expression of AGS1/ RASD1 on A549 cell growth in vitro and in vivo. Adenoviral constructs were generated using the pShuttle-CMV-pAdEASY-1 system in the LSUHSC vector core facility by standard procedures. For infection, A549 cells were plated in duplicate either on a sixwell plate or a 100 mm dish at a density of 1-5 Â 10 5 cells 24 h prior to infection (multiplicity of infection (MOI) 1-300) in a low serum media (2%). The medium containing the virus was replaced with medium containing 10% serum after 24 h. (a) Growth curve in A549 cells. A549 cells infected with empty vector control (Ad.Vector, circles), Ad.AGS1 (triangle), Ad.AGS1-G31V ( Â ). Control cells -no virus infection (Control, squares). Cells were harvested at the indicated time points and counted with a hemocytometer. Trypan blue was used to stain dead cells. Each point represents the mean of duplicate samples and the data are representative of results obtained in three different experiments. Inset, expression of AGS1 following cell infection was determined by immunoblotting using an affinity-purified polyclonal antisera that was generated using a 20 aa peptide (Cys 214 -Gly 233 ) from the unique C-terminal extension of human AGS1/RASD1. In all, 75 mg of whole-cell lysates (1% SDS) was loaded in each lane. The immunoblot is representative of three different experiments. Plaque-based assays with non-packaging cell lines and RT-PCR indicated that there was no wild-type adenoviral contamination of the samples, indicating that the observed decrease in growth must reflect the expression of AGS1/RASD1 rather than effects of replicative virus. (b) Tumorigenicity assays were performed with 6-8-week-old immunocompromised athymic nude mice (NCR nu/nu, Charles River, Wilmington, MA, USA), as previously described (Lanson et al., 2003) . A549 cells were seeded onto 150-mm dishes at a density of 1 Â 10 7 cells 24 h prior to infection (MOI -100). UV-Ad.AGS1 -UV inactivated AGS1 adenovirus. At 24 h after infection, the cells were harvested, counted and viability assessed by trypan blue exclusion. 1 Â 10 7 viable cells were resuspended in 200 ml of phosphate buffer (PB) and injected subcutaneously into 6-8-week athymic (NCR nu/nu) mice in the rear flanks. Five animals were used in each group. Tumor formation was monitored twice a week and measured using a digital caliper (tumor length Â tumor width 2 Â 0.5). Inset, a portion of the A549 cells that were used to inject into the athymic nude mice was replated and allowed to grow in vitro for 6 days and analysed for protein expression AGS1/RASD1 suppresses cell growth G Vaidyanathan et al . A549 cells were seeded onto 100-mm dishes at a density of 2 Â 10 5 cells and infected as described in the legend to Figure 2 . At different time points after infection, the supernatant was removed and combined with trypsinized cells followed by washing in phosphate buffer. Cells were fixed with 70% ethanol and stored at À201C for at least 24 h. Prior to FACS analysis, cells were pelleted to remove ethanol, followed by two washes in phosphate buffer. The cells were then stained in 1 ml of DNA-staining solution consisting of propidium iodide (20 mg/ml) and RNaseA (200 mg/ml) for 30 min at room temperature in the dark and analysed by flow cytometry (FACSCalibur, Becton and Dickinson). . At 72 h post infection, the cells were treated with aphidicolin (3 mg/ml) or nocodazole (300 ng/ml) for B20-30 h in media containing 2% serum to synchronize the cells in G 1 /S or G 2 /M interphase, respectively, and cell cycle evaluated by FACS analysis. Data shown are representative of two independent experiments performed in duplicate AGS1/RASD1 suppresses cell growth G Vaidyanathan et al receptor agonist thrombin (Vaidyanathan G and Lanier SM. Unpublished observations). Cell fractionation of tissue lysates homogenized in non-detergent buffer indicated that, in heart, liver and kidney, AGS1/RASD1 was restricted to the 100 000 g supernatant, whereas in brain the protein was also associated with the 100 000 g pellet (Vaidyanathan G and Lanier SM. Unpublished observations). The subcellular distribution of AGS1/ RASD1, which is likely a point of regulation, may be cell-type specific.
The reduction in clonal expansion and cell growth observed with AGS1/RASD1 expression also does not likely involve the potential direct activation of heterotrimeric G-protein such as G ia1-3 by AGS1/RASD1 (Cismowski et al., , 2000 Graham et al., 2001) or the apparent competition of AGS1/RASD1 for G iproteins (Graham et al., 2002; Takesono et al., 2002) , as the growth-inhibitory effect of AGS1/RASD1 in clonogenic assays was not altered by pertussis toxin, which ADP ribosylates G ia1-3 eliminating activation by a Gprotein coupled receptor or AGS1/RASD1 (Cismowski et al., 2000) (Pertussis toxin was added to the media (100 ng/ml) just after cell transfection and fresh media containing pertussis toxin (100 ng/ml) was added every 2-3 days for 1 week. In some experiments, pertussis toxin was added just prior to transfection and continued for 1 week, with fresh additions of pertussis toxin upon changing of cell culture medium. These experimental conditions are routinely used in our laboratory to disrupt receptor-mediated activation of G i /G o proteins in multiple cell types including NIH-3T3 cells.). In addition, constitutively active mutants of G i a 2 or activation of receptors coupled to G i -proteins actually lead to cellular transformation (Gutkind, 1998; Gudermann et al., 2000) , which contrasts with the growthinhibitory effects of AGS1/RASD1. At this stage, the relative contribution of heterotrimeric G-proteindependent and -independent signaling in the cell responses mediated by AGS1/RASD1 is not clear and this is indeed an area of active investigation. A better understanding of the role of heterotrimeric Gproteins in various cellular actions of AGS1/RASD1 will be greatly facilitated by identification of proteins or stimuli that regulate the activation state of AGS1/ RASD1 and the downstream binding partners of AGS1/ RASD1. Subsequent studies indicated that the lack of increase in cell number following Ad.AGS1 infection was associated with a 3-6-fold increase in trypan blue and propidium iodide-positive cells as compared to Ad.Vector or Ad.AGS1-G31V infected cells (Figure 4a , left panel). Etoposide served as positive control for the assay. AGS1 may repress cell growth by either actively promoting apoptosis and/or influencing cell cycle progression. Ad.AGS1 infection indeed increased the number of cells undergoing early apoptosis, as determined by double staining with Annexin V and propidium iodide and immunoblotting for cleavage of poly(ADP-ribose) polymerase-1 (PARP-1) (Figure 4a , middle and right panel). A snapshot of the cell cycle following AGS1/RASD1 expression indicated a significant decrease in the G 1 and S cell population and an increase in the sub-G 1 population (Figure 4b ). The relative distribution of cells at different phases of the cycle was also determined in cells that had been synchronized at either G 1 /S (aphidicolin) or G 2 /M (nocodazole) to provide a broader picture of the ability of the infected cells to move through the different stages of the cell cycle. Ad.AGS1-infected cells were not different from uninfected and empty vector controlinfected cells following 24 h treatment with aphidicolin in that the largest percentage of cells were at G 1 as expected (Figure 3c, top panel) . When cells were arrested at G 2 /M, Ad.AGS1-infected cells differed from control in that there was a greater proportion of cells that remained in G 0 /G 1 , suggesting that AGS1/RASD1 produced a slight delay in cell cycle progression (Figure 4c, lower panel) . Thus, the major action by which AGS1/RASD1 prevented cell proliferation involved the apparent activation of apoptotic cell death.
AGS1/RASD1 falls into a functional grouping with three other Ras-like proteins (RIG, RERG, ARH1/ NOEY2), which were recently shown to suppress cell growth and/or exhibit altered expression in various tumors (Finlin et al., 2001; Ellis et al., 2002; Luo et al., 2003) . The AGS1/RASD1 gene maps to human chromosome 17p11.2, a region associated with a high incidence of loss of heterozygosity and deletions in cancers (Soenen et al., 1998; Stacey et al., 1999; Koga et al., 2002) . The current studies indicate that a component of aberrant cell growth in certain tissues may reflect a loss of the control mechanisms that maintain AGS1/RASD1 expression. Restoring AGS1/ RASD1 expression in three different cell lines resulted in a marked anti-growth effect in vitro and in vivo, indicating that therapeutic interventions that promote AGS1/RASD1 expression or target AGS1/RASD1-regulated effectors would be of value to treat various types of cancers.
